Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-1360.61%
operating margin TTM
-1408.73%
revenue TTM
19.60 Million
revenue per share TTM
0.32$
valuation ratios | |
|---|---|
| pe ratio | -1.06 |
| peg ratio | -0.09 |
| price to book ratio | 1.36 |
| price to sales ratio | 6.77 |
| enterprise value multiple | -1.08 |
| price fair value | 1.36 |
profitability ratios | |
|---|---|
| gross profit margin | 92.41% |
| operating profit margin | -1408.73% |
| pretax profit margin | -1360.61% |
| net profit margin | -1360.61% |
| return on assets | -61.54% |
| return on equity | -91.94% |
| return on capital employed | -70.71% |
liquidity ratios | |
|---|---|
| current ratio | 6.65 |
| quick ratio | 6.65 |
| cash ratio | 6.41 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 1,212.98 |
| cash conversion cycle | -1,212.98 |
| receivables turnover | 0.00 |
| payables turnover | 0.30 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.30 |
| debt equity ratio | 0.62 |
| long term debt to capitalization | 0.35 |
| total debt to capitalization | 0.38 |
| interest coverage | -46.31 |
| cash flow to debt ratio | -2.04 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.96 |
| cash per share | 0.99 |
| operating cash flow per share | -0.94 |
| free cash flow operating cash flow ratio | 1.02 |
| cash flow coverage ratios | -2.04 |
| short term coverage ratios | -16.40 |
| capital expenditure coverage ratio | -41.43 |
Frequently Asked Questions
When was the last time TScan Therapeutics, Inc. (NASDAQ:TCRX) reported earnings?
TScan Therapeutics, Inc. (TCRX) published its most recent earnings results on 06-05-2026.
What is TScan Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. TScan Therapeutics, Inc. (NASDAQ:TCRX)'s trailing twelve months ROE is -91.94%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. TScan Therapeutics, Inc. (TCRX) currently has a ROA of -61.54%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did TCRX's net profit margin stand at?
TCRX reported a profit margin of -1360.61% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is TCRX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.65 in the most recent quarter. The quick ratio stood at 6.65, with a Debt/Eq ratio of 0.62.